William J Gradishar

  • 13146 Citations
1988 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

Filter
Comment/debate
2017

Triple-negative breast cancer: Current practice and future directions

Costa, R. L. B. & Gradishar, W. J., May 1 2017, In : Journal of oncology practice. 13, 5, p. 301-303 3 p.

Research output: Contribution to journalComment/debate

16 Scopus citations
2015

Refining treatment decisions in older patients with breast cancer

Flaum, L. & Gradishar, W. J., May 1 2015, In : JAMA Oncology. 1, 2, p. 166-167 2 p.

Research output: Contribution to journalComment/debate

2014

Quality of life in patients with metastatic breast cancer

Gradishar, W. J., Feb 1 2014, In : Clinical Advances in Hematology and Oncology. 12, 2, p. 3-4 2 p.

Research output: Contribution to journalComment/debate

2012

Paclitaxel matches nab-paclitaxel, passes ixabepelone: Commentary

Gradishar, W. J., Jul 1 2012, In : Oncology Report. JULY, 1 p.

Research output: Contribution to journalComment/debate

Trastuzumab in regimens raises cardiotoxicity fivefold: Commentary

Gradishar, W. J., May 1 2012, In : Oncology Report. MAY, 1 p.

Research output: Contribution to journalComment/debate

2011

Breast density taking center stage in legislative agendas: Commentary

Gradishar, W. J., Nov 1 2011, In : Oncology Report. NOVEMBER-DECEMBER, 1 p.

Research output: Contribution to journalComment/debate

Exemestane prevents 65% of invasive Ca post menopause: Commentary

Gradishar, W. J., Jul 1 2011, In : Oncology Report. JULY-AUGUST, 1 p.

Research output: Contribution to journalComment/debate

HRT doesn't worsen breast cancer risk following oophorectomy: Commentary

Gradishar, W. J., Jul 1 2011, In : Oncology Report. JULY-AUGUST, 1 p.

Research output: Contribution to journalComment/debate

Multimodal DCIS therapy with tamoxifen cuts breast ca deaths: Commentary

Gradishar, W. J., Nov 1 2011, In : Oncology Report. NOVEMBER-DECEMBER, 1 p.

Research output: Contribution to journalComment/debate

ODAC backs yanking avastin indication in MBC: Commentary

Burris, H. A., Gradishar, W. J. & Rugo, H. S., Jul 1 2011, In : Oncology Report. JULY-AUGUST, 1 p.

Research output: Contribution to journalComment/debate

Regional nodal irradiation combats disease recurrence: Commentary

Gradishar, W. J., Jul 1 2011, In : Oncology Report. JULY-AUGUST, 1 p.

Research output: Contribution to journalComment/debate

2010

Assay results often lead to change in breast Ca treatment plan: Commentary

Gradishar, W. J., Mar 15 2010, In : Oncology Report. JANUARY-FEBRUARY, 1 p.

Research output: Contribution to journalComment/debate

A third of refractory patients respond to trastuzumab-DM1: Commentary

Gradishar, W. J., Mar 15 2010, In : Oncology Report. JANUARY-FEBRUARY, 1 p.

Research output: Contribution to journalComment/debate

CONFIRM trial: Fulvestrant 500 mg better than standard dosing: Commentary

Gradishar, W. J., Mar 15 2010, In : Oncology Report. JANUARY-FEBRUARY, 1 p.

Research output: Contribution to journalComment/debate

Distant metastasis and death more likely in obese women: Commentary

Gradishar, W. J., May 20 2010, In : Oncology Report. MARCH-APRIL, 1 p.

Research output: Contribution to journalComment/debate

Dual HER2 blockade boosts survival in metastatic cases: Commentary

Gradishar, W. J., Mar 15 2010, In : Oncology Report. JANUARY-FEBRUARY, 1 p.

Research output: Contribution to journalComment/debate

Postmastectomy recurrence rates low without radiation: Commentary

Gradishar, W. J., May 20 2010, In : Oncology Report. MARCH-APRIL, 1 p.

Research output: Contribution to journalComment/debate

RIBBON 2: Adding second-line bevacizumab improves PFS: Commentary

Gradishar, W. J., Mar 15 2010, In : Oncology Report. JANUARY-FEBRUARY, 1 p.

Research output: Contribution to journalComment/debate

2009

Crossover order does not affect survival in metastatic patients: Commentary

Gradishar, W. J., Sep 1 2009, In : Oncology Report. FALL, 1 p.

Research output: Contribution to journalComment/debate

In the pipeline: Trastuzumab-DM1 active after HER2 therapy fails - Commentary

Gradishar, W. J., Sep 1 2009, In : Oncology Report. FALL, 1 p.

Research output: Contribution to journalComment/debate

PARP inhibitors target triple-negative, BRCA1/2 cancers: Commentary

Gradishar, W. J., Sep 1 2009, In : Oncology Report. FALL, 1 p.

Research output: Contribution to journalComment/debate

RIBBON-1: Avastin raises PFS, not overall survival - Commentary

Gradishar, W. J., Sep 1 2009, In : Oncology Report. FALL, 1 p.

Research output: Contribution to journalComment/debate

SOLTI-0701 trial: Sorafenib active in advanced breast cancer - Commentary

Gradishar, W. A., Dec 1 2009, In : Oncology Report. WINT, 1 p.

Research output: Contribution to journalComment/debate

Surgery on primary tumor improves metastatic survival: Commentary

Gradishar, W. A., Dec 1 2009, In : Oncology Report. WINT, 1 p.

Research output: Contribution to journalComment/debate

2008

Supporting patients with metastatic breast cancer: A call to action

Gradishar, W. J., Dec 2008, In : Community Oncology. 5, 12, p. 647-648 2 p.

Research output: Contribution to journalComment/debate

2006

Adding carboplatin fails to boost efficacy of docetaxel and trastuzumab: Comment

Gradishar, W. J., Sep 1 2006, In : Oncology Report. FALL, 1 p.

Research output: Contribution to journalComment/debate

Combination of lapatinib and capecitabine provides significant benefit in metastatic disease: Comment

Rugo, H. S. & Gradishar, W. J., Sep 1 2006, In : Oncology Report. FALL, p. 15-19 5 p.

Research output: Contribution to journalComment/debate

Equivalent efficacy for exemestane and anastrozole in advanced breast cancer: Comment

Gradishar, W. J., Sep 1 2006, In : Oncology Report. FALL, p. 27-28 2 p.

Research output: Contribution to journalComment/debate

Ixabepilone shows promising clinical activity in metastatic breast cancer: Comment

Gradishar, W. J., Sep 1 2006, In : Oncology Report. FALL, p. 20-21 2 p.

Research output: Contribution to journalComment/debate

Monoclonal antibody to RANK-L shows bone protection potential: Comment

Gradishar, W. J., Sep 1 2006, In : Oncology Report. FALL, 1 p.

Research output: Contribution to journalComment/debate

Raloxifene is as effective as tamoxifen in preventing primary invasive breast cancer: Comment

Gradishar, W. J., Sep 1 2006, In : Oncology Report. FALL, 1 p.

Research output: Contribution to journalComment/debate

2005

Changes in circulating endothelial and tumor cells may mark anti-angiogenesis. Comment

Gradishar, W. J., Sep 1 2005, In : Oncology Report. FALL, p. 32-33 2 p.

Research output: Contribution to journalComment/debate

Older breast cancer patients can forego RT. Comment

Gradishar, W. J., Sep 1 2005, In : Oncology Report. FALL, p. 17-18 2 p.

Research output: Contribution to journalComment/debate

2000

Postmastectomy radiation for young woman with poorly differentiated adenocarcinoma of the breast?

Gradishar, W. J. & Fowble, B., Dec 1 2000, In : Cancer Case Presentations: The Tumor Board. 4, 6, p. 89-91 3 p.

Research output: Contribution to journalComment/debate

1998

Corrigendum: High-dose chemotherapy, autologous bone marrow or stem cell transplantation and post-transplant consolidation chemotherapy in patients with advanced breast cancer (Bone Marrow Transplantation (1997) 20 (721-729))

Tallman, M. S., Rademaker, A. W., Jahnke, L., Brown, S. G., Bauman, A., Mangan, C., Kelly, C., Rubin, H., Kies, M. S., Shaw, J., Kiel, K., Gordon, L. I., Gradishar, W. J. & Winter, J. N., 1998, In : Bone Marrow Transplantation. 21, 8, 1 p.

Research output: Contribution to journalComment/debate

Open Access